NCT02345408View on ClinicalTrials.gov

Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 6, 2020

Study Completion Date

May 6, 2020

Conditions

Pancreatic Cancer

Interventions

DRUG

CCX872-B

Tablets (oral administration)

Trial Locations (6)

Unknown

St Louis

Rochester

Amsterdam

Nijmegen

Netherland, Rotterdam

Sittard

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY